bluebird bio, Inc. (BLUE) has signed first Medicaid outcomes-based agreement for LYFGENIA with the state of Michigan. LYFGENIA is a one-time gene therapy approved for the treatment of patients 12 years of age and older with sickle cell disease and a history of vaso-occlusive events.